Reports Q3 revenue $138.96M, consensus $133.23M. “We delivered strong financial results in the third quarter, including double-digit organic growth and significantly increased cash flow,” said Rob Claypoole, Bioventus (BVS) President and Chief Executive Officer. “We remain focused on successfully executing on our strategic priorities to accelerate revenue growth, enhance profitability, and reduce our leverage to increase shareholder value.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS:
- Bioventus, Inc. (BVS) Q3 Earnings Cheat Sheet
- Bioventus files $200M mixed securities shelf
- Bioventus files to sell 35.04M shares of Class A common stock for holders
- Bioventus divesting advanced rehabilitation business to Accelmed Partners
- Bioventus price target raised to $17 from $12 at Craig-Hallum